- Home
- IMA
IMA
ImageneBio Inc.
as 11-14-2025 2:07pm EST
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 92.2M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 68.3K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.24 - $23.28 | Next Earning Date: | 11-12-2025 |
| Revenue: | $800,000 | Revenue Growth: | -89.95% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ImageneBio Inc. News
IMA Breaking Stock News: Dive into IMA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation
GlobeNewswire
4 days ago
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Compare IMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMA ImageneBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.